Table 1 Patient demographics

From: C3a receptor antagonism as a novel therapeutic target for chronic rhinosinusitis

A. Plasma samples

 

Control (n = 7)

CRSwNP (n = 18)

p Value

Sex, no. (%)

  

0.9428

 Men

3 (42.9)

8 (44.4)

 

 Women

4 (57.1)

10 (55.6)

 

Age, mean ± SD

47.4 ± 23.6

40.2 ± 18.5

0.1629

Race, no. (%)

  

0.4090

 White

3 (42.9)

11 (61.1)

 

 African American

4 (57.1)

7 (38.9)

 

 Other

0 (0)

0 (0)

 

SNOT22 score, mean ± SD

—

49.3 ± 27.8 [14]

—

B. Nasal mucus samples

 

Control (n = 6)

CRSwNP (n = 11)

p Value

Sex, no. (%)

  

0.7933

 Men

4 (66.7)

8 (72.72)

 

 Women

2 (33.3)

3 (27.3)

 

Age, mean ± SD

35.5 ± 14.5

42.45 ± 21.92

0.4985

Race, no. (%)

  

0.6905

 White

4 (66.7)

7 (63.64)

 

 African American

2 (33.3)

3 (27.27)

 

 Other

0 (0)

1 (9.1)

 

SNOT22 score, mean ± SD

—

49.625 ± 20.27 [8]

—

  1. SNOT22 sinonasal outcome test-22, SD standard deviation, [n] number of patients with available SNOT22 scores
Back to article page